Vanda Pharmaceuticals (VNDA) Leases (2019 - 2026)

Vanda Pharmaceuticals' Leases history runs 8 years deep, the most recent figure standing at $7.3 million for Q1 2026.

• In Q1 2026, Leases rose 39.86% year-over-year to $7.3 million; the TTM figure through Mar 2026 stood at $7.3 million (up 39.86% YoY), while the FY2025 annual figure was $7.3 million, up 31.08% from the prior year.
• Leases came in at $7.3 million for Q1 2026 at Vanda Pharmaceuticals, down from $7.3 million in the prior quarter.
• In the past five years, Leases ranged from a high of $8.9 million in Q1 2022 to a low of $4.4 million in Q3 2025.
• A 5-year average of $7.0 million and a median of $7.3 million in 2026 frame the typical range for Leases.
• Across the five-year window, Leases fell 27.39% in 2025 and surged 39.86% in 2026, its largest moves.
• Vanda Pharmaceuticals' Leases stood at $8.4 million in 2022, then decreased by 15.44% to $7.1 million in 2023, then slipped by 21.13% to $5.6 million in 2024, then surged by 31.08% to $7.3 million in 2025, then declined by 0.8% to $7.3 million in 2026.
• According to Business Quant data, Leases over the past three periods registered $7.3 million, $7.3 million, and $4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison